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Effects of C-peptide on glomerular and renal size and renal glomerular hyperfiltration, which can be observed soon
function in diabetic rats. after diabetes onset [1, 2]. Glomerular hyperfiltration is
Background. Strict glycemic control and antihypertensive often accompanied by a loss of renal functional reservetreatment may decrease but not eliminate the risk of progres-
(RFR) [3]. After some years, microalbuminuria (30 tosive nephropathy in diabetic patients. C-peptide has been
shown to exert beneficial effects on complications, including 300 mg/day) may occur [4] as well as morphological
incipient nephropathy, in type 1 diabetes. changes such as thickening of the glomerular basement
Methods. Renal effects of 14 days of intravenous infusion membrane and mesangial expansion [5]. The albumin
of C-peptide or NaCl (placebo) were studied in three groups
leakage may subsequently become aggravated and overtof rats: one nondiabetic NaCl-treated (normal, N  7), one
nephropathy with albuminuria (300 mg/day) may de-streptozotocin diabetic NaCl-treated (D-placebo, N  7), and
one streptozotocin diabetic C-peptide-treated group (D-C-p, velop, usually 10 to 20 years after the onset of diabetes.
N 7). Metabolic data and albuminuria were measured in meta- At this time, hypertension becomes more common. Ne-
bolic cages every fourth day. After 14 days, the glomerular filtra-
phrotic syndrome may occur, and glomerular filtrationtion rate (GFR) was measured by inulin clearance and available
rate declines. The most important therapeutic measuresrenal functional reserve (RFR) by glycine infusion, whereupon
one kidney was perfusion fixed for morphological studies. undertaken to avoid, or retard, the progress of nephropa-
Results. Glucose levels were 36.7 1.3 and 34.0 1.7 mmol/L thy aim to improve glycemic control [6–8] and normalize
in the D-placebo and D-C-p groups, respectively. The D-pla- blood pressure [9–11]. Angiotensin-converting enzymecebo group presented a 32% (P  0.001) larger glomerular
inhibitors have proven effective in the latter respect andvolume than the D-C-p group. The D-placebo group also pre-
also are beneficial in normotensive type 1 diabetic pa-sented a significantly larger renal weight than the normal group
in contrast to the D-C-p group. Urinary albumin excretion tients [11, 12]. However, despite these efforts, progres-
increased in the D-placebo group in contrast to the other sive nephropathy is seen often, in some cases leading to
groups. GFR was 1.72 0.12 mL/min (normal), 3.73 0.19 mL/
end-stage renal disease. Thus, additional factors aremin (D-placebo, P  0.001 vs. normal) and 2.16  0.16 mL/
likely involved in this process. A lack of C-peptide maymin (D-C-p, nonsignificant vs. normal). Available RFR was
93 25% (normal), 10 4% (D-placebo, P 0.05 vs. normal) be one such factor.
and 57 13% (D-C-p, nonsignificant vs. normal) of basal GFR. Earlier, C-peptide was considered to be without any
Conclusions. Physiological doses of homologous C-peptide biological activity [13, 14] other than to facilitate the
prevent the development of glomerular hypertrophy, albumin-
folding of the proinsulin molecule in the proper way touria, and glomerular hyperfiltration in rats with experimentally
permit formation of disulfide bridges between the - andinduced diabetes.
-chains of the insulin molecule [15].
However, several studies in recent years have demon-
Nephropathy is one of the most common and most strated a series of physiological effects of the C-peptide
serious complications in type 1 diabetes mellitus. Renal itself in animals and in patients with type 1 diabetes mel-
involvement usually starts with renal hypertrophy and litus. For example, studies in young type 1 diabetic patients
with microalbuminuria have revealed beneficial effects
of C-peptide on glomerular hyperfiltration and urinaryKey words: diabetic nephropathy, glomerular hypertrophy, hyperfil-
tration, renal functional reserve, albuminuria. albumin excretion [16–18]. Furthermore, short-term in-
fusion of supraphysiological doses of human C-peptide
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The mechanism by which C-peptide exerts its effects excretion, and osmolality. Blood samples for blood glu-
has not been established. Stimulation of Na,K-ATPase cose measurements were taken from the tip of the tail.
activity by C-peptide has been demonstrated in renal
Determination of GFR and RFRtubular cells [20, 21] and in neural tissue [22]. C-peptide
may also stimulate endothelial nitric oxide synthase After 14 days, the rats were anesthetized by an intra-
[eNOS; abstract; Kunt et al, Diabetologia 41(Suppl 1): peritoneal injection of Inactin (sodium 5-sec-butyl-5-
A176, 1998]. Specific binding of C-peptide to a G-protein– ethyl-2-thiobarbiturate; RBI, Natick, MA, USA) at 120
coupled membrane receptor has been demonstrated for mg/kg body weight, and then placed on a servo-controlled
several different cell types, including renal tubular cells heating pad to maintain the body temperature at approx-
[23] and renal mesangial cells (personal communication imately 37.5C. To facilitate spontaneous breathing, a
with R. Rigler, the first author of [23]), and the evidence cannula was inserted into the trachea. The right femoral
is accumulating that C-peptide may be an endogenous artery was cannulated for blood sampling and for mea-
peptide hormone. surements of the arterial blood pressure. The right femo-
The main objective of the present study was to investi- ral vein was cannulated for infusions. The bladder was
gate the effects of C-peptide on renal morphology (glo- catheterized via a suprapubic incision.
merular volume and renal size) in diabetic rats. These Immediately after surgery, arterial blood was drawn
effects have not been studied previously and would be far to determine blood glucose and sodium and potassium
more complicated to study in diabetic patients. We also concentrations. Thereafter, an infusion of a Ringer solu-
evaluated the effects of long-term infusion of homologous tion containing 129 mmol/L NaCl, 25 mmol/L NaHCO3,
C-peptide in physiological doses on renal hyperfiltration, 2.5 mmol/L KCl, 0.75 mmol/L CaCl2, and fluorescein
renal functional reserve, and urinary albumin excretion. isothiocyanate (FITC)-labeled inulin (Pharmacia AB,
Uppsala, Sweden) 4 mg/mL was started. The infusion
rate was 5 mL 	 h
1 	 kg
1 body weight following aMETHODS
bolus dose of 1 mL. The Ringer solution also was usedEight-week-old male Sprague-Dawley rats (Møllgaard,
as a vehicle for glycine when infused.Copenhagen, Denmark) with an initial weight of approx-
When steady state had been reached, after approxi-imately 200 g were studied in three groups: normal rats
mately 45 minutes, urine samples were collected at 15-treated with isotonic NaCl (normal group, N  7), dia-
minute intervals for analyses of urine volume, osmolar-betic rats treated with isotonic NaCl (D-placebo group,
ity, albumin excretion rate, and sodium and potassiumN  7), and diabetic rats treated with rat C-peptide 2
concentrations. Plasma samples (60 L) for analyses(D-C-p group, N  7; Genosys Biotechnologies, UK).
of FITC-labeled inulin were obtained at the midpointAll animals had free access to tap water and standardized
of each 15-minute urine collection period, thus makingchow (R36; Lactamin) throughout the study period. Dia-
calculation of GFR possible. After two 15-minute peri-betes was induced by intravenous injection of strepto-
ods when the basal GFR was measured, infusion of gly-zotocin 60 mg/kg body weight. Treatment with either
cine (0.22 mmol 	 kg
1 	 min
1) was started, for deter-C-peptide (50 pmol 	 kg
1 	 min
1) or NaCl (which
mination of the available RFR, and maintained for thewas also the vehicle for C-peptide) was initiated at diabe-
remaining 60 minutes of the experiment.tes onset (blood glucose15 mmol/L) and administered
as a continuous intravenous infusion for two weeks by
Perfusion fixation of the kidneyan osmotic pump (type 2002; Alzet, USA) attached to
When GFR and RFR measurements had been com-a catheter inserted into the right jugular vein. The pump
pleted, blood samples for determination of C-peptidewas placed in the subcutaneous tissue of the neck. The
and sodium and potassium concentrations were takenrats were not treated with insulin.
and immediately substituted by an equal volume ofThe study protocol was reviewed and approved by the
Ringer solution (without glycine) to maintain renal per-local animal ethics committee.
fusion. Thereafter, the left kidney, the renal vessels, and
Metabolic cages aorta were exposed via a subcostal incision. The catheter
earlier inserted via the femoral artery was adjusted to theBefore streptozotocin treatment and on days 4, 8, and
level of the left renal artery. The aorta was subsequently12 after diabetes onset and start of treatment, all rats were
ligated proximally and distally to the left renal artery.put in metabolic cages (Tecniplast Gazzada 3701MO-
Immediately after the ligation, the left kidney was per-000, Buguggiate, Italy) for 24 hours. Body weight, daily
fused with 4% paraformaldehyde in 0.1 mol/L phosphateintake of water and food, and excretion of urine and
buffer (pH 7.4) at a pressure adjusted to the mean arterialfeces were measured individually. Urine samples were
collected for analyses of albumin, sodium and potassium blood pressure just before the perfusion was started.
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Analyses ysis of variance for repeated measurements within each
group followed by the Tukey post hoc test. For compari-FITC-labeled inulin was analyzed in a Ploemopak
sons of available RFR between groups the mean percent-fluorescence microscope (Leitz Dialux 22 EB, Germany)
age increases of GFR during the glycine infusion periodequipped with a photometer (Leitz MPV compact, Ger-
were compared by analysis of variance (ANOVA) fol-many). Measurements were made from the central por-
lowed by the Tukey post hoc test. Data are presentedtion of the sample after it had been transferred to con-
as means  SEM except for Tukey box and whiskerstant-bore capillaries (0.5 L; Microcaps, Drummond,
plots in Figures 1, 3, and 4 (details are in the legends).USA) [24]. Plasma concentrations of C-peptide were
measured by radioimmunoassay (RIA; Linco Research
RESULTSInc., USA). Urine volumes were determined gravimetri-
cally. Urinary sodium and potassium concentrations were Data from the metabolic cages
determined by flame photometry (IL 543; Instrumenta- Table 1 shows the results obtained from the metabolic
tion Lab., Milano, Italy) and urine osmolality by a freez- cages in the basal state before streptozotocin treatment
ing point depression method (Model 3 MO; Advanced and 12 days after onset of diabetes mellitus in the three
Instruments, MA, USA). The urine albumin concentra- study groups. Before streptozotocin treatment, the data
tion was measured by nephelometry. Blood glucose con- of the three study groups were similar, as expected, show-
centrations were analyzed by means of Accutrend (Boeh- ing no statistically significant differences in blood glu-
ringer Mannheim GmbH, Mannheim, Germany) when cose, body weight, food intake, water intake, feces weight,
obtained from the rat’s tail and by a glucose oxidase urine volume, urine osmolarity, or excretion of sodium
method (Glucose Analyzer; Yellow Spring Instruments, and potassium in the urine. Twelve days after streptozo-
USA) when obtained at the end of the final experiment. tocin treatment, the two diabetic groups had reached
The mean glomerular volume was estimated by Cava- high and similar glucose concentrations. The diabetic
lieri’s principle [25]. The left kidney was weighed and groups also presented polydipsia, polyuria, polyphagia,
cut into 1.4 mm thick slices using a device with parallel reduced growth rate, and increased fecal excretion as a
result of their diabetes. All of these changes were sta-razor blades. From each rat, two systematically and ran-
tistically significant both when compared within groupsdomly sampled slices were embedded in glycol methacry-
to the basal state and in comparison to the normal group.late (Technovit 7100, Kulzer, Werheim, Germany). The
The changes were already present on days 4 and 8 afterplastic blocks were cut in 3.0 m thick consecutive sec-
the streptozotocin treatment, although these data are nottions, which were stained with PAS. Fifteen superficial
presented in the table. On the other hand, no statisticallyglomeruli were analyzed per animal. At 15 m intervals,
significant differences in these variables were found be-the profile areas of glomerular tufts completely included
tween the two diabetic groups, except for a higher fecalwithin the serial sections were point counted using an
excretion in the D-placebo group.ocular grid with 32.1 m ( d) between each point ( p)
Urine osmolarity was markedly reduced, and the ex-at tissue level (	420). The sum of the profile areas (A
creted amounts of sodium and potassium were elevatedSUM) of a glomerulus was determined according the
in the two diabetic groups compared with the normalformula A SUM  pTOT*d2, where pTOT is the sum of the group. The sodium:potassium excretion ratio was 0.73points hitting all the sampled profile areas of the same
0.08 in the normal, 0.65  0.01 in the D-C-p, and 0.59 glomerulus.
0.03 in the D-placebo group. The lower ratios observed
For the final calculation of the glomerular volume, the
in the diabetic groups were not significantly different
mean of the actual section thickness was measured by from the normal group.
confocal microscopy as described by Brismar et al [26]. Plasma C-peptide concentration in the D-C-p group,
Briefly, the x-z profile of a section was scanned by confo- measured on day 14, was within physiological limits (Ta-
cal microscopy. The full-width half maximum of the in- ble 1).
tensity profile in the axial direction of the x-z profile was
then used as an estimate of the actual section thickness. Glomerular volume and renal weight
The glomerular volume was 0.92  0.05 	 106 m3 in
Statistical methods and data presentation the normal group, 1.50  0.06 	 106 m3 or 63% larger
Significant differences in metabolic data, glomerular (P  0.001 vs. normal) in the diabetic placebo-treated
volume, renal size, and basal GFR were calculated by group, and 1.13  0.06 	 106 m3 (nonsignificant vs.
analysis of variance followed by the Tukey post hoc test. normal) in the diabetic C-peptide–treated group (Fig. 1).
RFR for each time interval observed and albuminuria The D-placebo group presented a 32% (P 0.001) larger
(in the latter after the values had been logarithmically glomerular volume than D-C-p group.
The renal weight (data not shown) was 31% larger intransformed) was compared to the basal state using anal-
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Table 1. Metabolic data
Group Normal D-placebo D-C-p
Day after treatment start Basal Day 12 Basal Day 12 Basal Day 12 P
Blood glucose concentration mmol/L 6.70.2 8.80.8 6.90.1 36.71.3b 6.60.2 34.01.7b NS
C-peptide concentration nmol/L 1.30.3 0.150.02 1.50.4 0.01
Body weight g 2064 32111b 2072 2736b 2121 2717b NS
Urine volume mL/day 10.90.8 9.52.5 9.71.2 192.110.7b 10.10.9 177.211.2b NS
Water intake mL/day 29.61.4 30.92.1 29.11.3 222.312.9b 30.41.2 195.715.1b NS
Feces g/day 10.60.2 10.60.7 11.30.3 25.31.8b 11.40.9 17.60.8b 0.01
Food intake g/day 21.60.9 261.5 21.10.5 43.71.5b 22.30.5 412.3b NS
UOsm mOsm/kg 1372122 1957350 1534172 87025a 1478103 89126a NS
UNa mmol/day 1.900.08 2.10.3 1.710.08 4.00.5a 1.900.09 4.30.1b NS
UK mmol/day 2.890.27 2.90.2 2.710.15 6.70.7a 2.740.14 6.70.2b NS
Data are from metabolic cages one day before streptozotocin or placebo injection (basal) and 12 days after diabetes onset and implantation of the osmotic infusion
pumps in the three study groups: Normal NaCl-treated rats (Normal, N  7), Diabetic NaCl-treated rats (D-placebo, N  7) and Diabetic C-peptide–treated rats
(D-C-p, N  7). ANOVA followed by Tukey’s post-hoc test was used for the statistical analyses. Last column indicates differences between the D-C-p and D-placebo
groups on day 12. Data are presented as means  SEM.
a P  0.01, b P  0.001, significant changes from basal to day 12 within a group
Fig. 1. Glomerular volume 14 days after the
start of treatment. Tukey box and whisker plot.
The symbol () indicates the median value,
while the outer boxes represent the 25th and
the 75th percentiles and whiskers show the non-
outlier range. A value was defined as an out-
lier if it was more than 1.5 times the box height
above or below the box. Analysis of variance
followed by the Tukey post hoc test was used
for the statistical analysis. Asterisks indicate sta-
tistically significant differences between groups
(***P  0.001) and NS is nonsignificant.
the D-placebo group compared with the normal group in the basal state to 4.08  0.11 mL/min during the
glycine infusion. In the D-C-p group, the GFR increased(P  0.05). The D-C-p group did not differ significantly
from the normal group in this respect. by 57  13% (P  0.01), from 2.16  0.16 mL/min in
the basal state to 3.30  0.10 mL/min during the glycine
GFR and RFR infusion. The available RFR in the D-C-p group did
not differ significantly from that of the normal group,The basal GFR 14 days after diabetes onset is shown
in Figure 2. GFR in the normal rats was 1.72  0.12 mL/ whereas the RFR was absent or completely used in the
basal state in the D-placebo group.min. The D-placebo group presented a prominent hyper-
filtration, with a GFR of 3.73  0.19 mL/min or 117% When each time interval was compared with the basal
state, the D-placebo group did not present a statisticallyhigher than in the normal group (P  0.001) and 73%
higher than in the C-peptide–treated diabetic group (P significant increment in GFR at any measured time inter-
val during glycine infusion. In contrast, the D-C-p group0.001). The GFR in the D-C-p group was 2.16 0.16 mL/
min, which was slightly but not significantly higher than had a significantly increased GFR at every measured
time interval and the normal group at every measuredin the normal group.
During the glycine infusion period, GFR in the normal time interval from 45 minutes onward.
rats increased by 93  25% (P  0.01), from 1.72 
Albumin excretion0.12 mL/min in the basal state to an average of 3.25 
0.39 mL/min during the glycine infusion, representing The urinary albumin excretion showed a large interindi-
vidual and intraindividual variation (Fig. 4). However,the RFR (Fig. 3). In the D-placebo group, GFR increased
by 10  4% (nonsignificant) from 3.73  0.19 mL/min in the D-placebo group, the urinary albumin excretion
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Fig. 2. Glomerular filtration rate (GFR) 14
days after the start of treatment. GFR was
measured as clearance of inulin, before infu-
sion of glycine was started. Tukey box and
whisker plot. The symbol () indicates the
median value, while the outer box represents
the 25th and the 75th percentiles and whiskers
show the non-outlier range. A value was de-
fined as an outlier if it was more than 1.5
times the box height above or below the box.
Analysis of variance followed by Tukey’s post
hoc test was used for the statistical analysis.
Asterisks indicate statistically significant dif-
ferences between groups (***P  0.001) and
NS is nonsignificant.
Fig. 4. Urinary albumin excretion days 0, 4, 8, and 12 after treatment
start. Symbols are () normal group, N  7; () D-C-p group, N 
7; () D-placebo group, N  7. Analysis of variance for repeatedFig. 3. Glomerular filtration rate (GFR) 14 days after treatment start,
measurements followed by the Tukey post hoc test was used for thebefore, and during glycine infusion. GFR was measured as clearance
statistical analysis after the values had been logarithmically transformed.of inulin. Symbols are: () normal group, N  7; () D-C-p group,
Asterisks indicate statistically significant differences from the basalN  7; () D-placebo group, N  7. Analysis of variance for repeated
state within each group: *P  0.05; **P  0.01. Data are shown asmeasurements followed by the Tukey post hoc test was used for the
means  SEM.statistical analysis. Statistically significant differences, within one group,
from the basal state (before glycine infusion) are shown as **P  0.01
and ***P  0.001. Data are shown as means  SEM.
Our data show, to our knowledge for the first time, that
had increased significantly from the basal state on days C-peptide replacement in diabetic rats prevents the de-
4 (P  0.05), 8, and 12 (P  0.01) after the initiation of velopment of glomerular hypertrophy (Fig. 1). It also
treatment. Neither the D-C-p group nor the normal prevents the development of glomerular hyperfiltration
group showed any statistically significant increase in al- (Fig. 2) and albuminuria (Fig. 4), and restores the avail-
bumin excretion compared with the basal state. able RFR (Fig. 3) in spite of hyperglycemia.
Thus, the D-placebo group had a higher albumin ex- The aim of our study was to clarify the renal effects
cretion in the urine than the normal group in contrast of C-peptide, since several recent studies in both rats
to the D-C-p group. and patients suggested that, in contrast to earlier beliefs,
C-peptide is a biologically active hormone.
DISCUSSION While the effects of C-peptide on glomerular hyper-
trophy to our knowledge have not been studied before,The present findings indicate that a continuous two-
it is known that glomerular hyperfiltration and hypertro-week infusion of homologous C-peptide in physiological
phy often occur simultaneously [27]. We found that thedoses exerts biological effects when administered to rats
with experimentally induced type 1 diabetes mellitus. size of the glomeruli in the C-peptide–treated diabetic
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group did not differ significantly from the normal group by infusion of glycine for 60 minutes. The normal rats
and was significantly smaller than in the placebo treated increased their GFR by 93% (Fig. 3), representing the
diabetic group. However, there was a nonsignificant ten- RFR. The D-placebo rats did not increase their GFR
dency toward slightly larger glomeruli in the C-peptide– significantly during the glycine infusion (Fig. 3). Thus,
treated diabetic group compared with the normal group. this group displays a loss of RFR or a complete utilization
The process of glomerular hypertrophy starts very soon of RFR in the basal state (loss of available RFR) in
after diabetes onset [28]. Consequently, it is possible that congruence with data presented earlier [19]. In the D-C-p
the delay between the streptozotocin injection and the rats the available RFR was preserved, since GFR in-
start of C-peptide treatment (1 to 3 days) was sufficient creased by 57% when glycine was infused. The RFR in
to cause a slight, and for a 14-day period, irreversible the D-C-p rats did not differ significantly from the nor-
glomerular hypertrophy. It is also interesting to note mal rats.
that renal weight was simultaneously increased in the The normal and diabetic C-peptide–treated groups
D-placebo group, whereas the D-C-p group did not differ never reached the GFR of the diabetic placebo-treated
significantly from the normal group. group when glycine was infused and maximal GFR was
Glomerular hyperfiltration, usually 25 to 50% above presumed to be reached. This may be related to the
normal GFR, is seen in approximately one half of pa- glomerular hypertrophy seen in the diabetic placebo-
tients with type 1 diabetes of less than five years’ dura- treated group, resulting in an increase in total glomerular
tion [29]. Although still controversial, the patients pre- filtration area in this group. It follows that the other
senting with hyperfiltration have been proposed to be groups could not reach the same maximal GFR.
at increased risk for later development of overt diabetic Thus, the D-C-p group presented not only less hyper-
nephropathy [4, 30]. Earlier studies in humans have indi- filtration than the D-placebo group, but also a preserved
cated that C-peptide can reduce glomerular hyperfiltra- ability to respond physiologically to an amino acid load.
tion [16
18]. In one study of rats with streptozotocin- This was shown earlier for acute infusion of supraphysio-
induced diabetes mellitus, an acute (140 min) infusion logical doses of human C-peptide to diabetic rats [19].
of supraphysiological doses of human C-peptide normal- Now, our results show that this is not just a transient
ized the GFR [19]. effect, but persists for at least 14 days after the start of
The present study used a similar experimental model C-peptide treatment in rats with experimentally induced
as in the latter study, except that we administered physio- diabetes mellitus. Since glomerular hyperfiltration (al-
logical doses of homologous C-peptide administered for though still controversial) is proposed to be an important
a longer period (14 days). In accordance with previous risk factor for progression to overt diabetic nephropathy
studies on diabetic patients and rats [16–19], we found
[4, 30], the beneficial effect of C-peptide in this respect,
that hyperfiltration (117% higher GFR than in normal
shown in humans and rats, may well be physiologicallyrats) was present in the D-placebo group. The GFR
and pathophysiologically important.in the D-C-p group was only 26% higher (statistically
Another early finding in diabetic nephropathy is micro-nonsignificant) than in the normal group and significantly
albuminuria, probably caused by an increased number oflower than in the D-placebo group (Fig. 2). The mecha-
large pores [32], in combination with a decreased amountnism by which C-peptide mediates this effect is unknown.
of heparan sulfate (the major component of the chargeOne proposed mechanism of glomerular hyperfiltration
barrier) in the glomerular basement membrane [33]. Ear-is dilation of the afferent arteriole, resulting in increased
lier studies have indicated that C-peptide may decreaseglomerular blood flow and glomerular capillary pressure,
albuminuria in patients with type 1 diabetes [17, 18]. Inthereby causing a higher net filtration pressure [29]. An-
rats, it was shown that total proteinuria decreased whenother proposed mechanism of hyperfiltration is an in-
C-peptide was infused for 140 minutes [19]. In the pres-creased number of glomerular capillaries and to some
ent study, we observed that the diabetic placebo-treatedextent a dilation of the individual glomerular capillary
rats presented a significantly increased urinary albumin[28], leading to a glomerular hypertrophy, which in turn
excretion throughout the observation period comparedleads to an increased total glomerular filtration area.
with the basal state. This was neither the case for theWhether C-peptide acts on these variables is not known
normal rats nor for the diabetic C-peptide–treated rats.since they were not measured in the present study.
One might speculate that the underlying mechanismDetermination of RFR has been used to detect the
is a reduced intraglomerular blood pressure and GFR inpresence of hyperfiltration, assuming that pre-existing
the D-C-p group. However, the albumin/creatinine ratio inelevation of glomerular blood flow and intraglomerular
the urine also was significantly increased on day 12 com-blood pressure will prevent any further rise in GFR [3].
pared with the basal state in the D-placebo group, whichAnother proposed mechanism is that the loss of RFR is
was not the case for the other groups. The mechanism ofrather a result of a reduction in proximal tubular reab-
sorption [31]. In the present study, RFR was measured reduced albumin leakage in the present study is unknown
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